Related Experiment Videos
[Retinoid therapy for autoimmune diseases].
Hiroshi Fukasawa1, Hiroyuki Kagechika, Koichi Shudo
1Department of Drug Development, Institute of Medicinal and Molecular Design, Inc.
Summary
Retinoids, including synthetic compounds like tamibarotene, show potential for treating autoimmune diseases. These compounds target retinoic acid receptors, offering new therapeutic avenues for conditions like rheumatoid arthritis.
Area of Science:
- Nuclear hormone receptor superfamily
- Retinoid signaling pathways
Context:
- Retinoids, such as all-trans-retinoic acid (ATRA), are endogenous compounds activating retinoic acid receptors (RARs) and retinoid X receptors (RXRs).
- ATRA and its analogs are clinically used for acute promyelocytic leukemia (APL) and dermatological conditions.
- Synthetic retinoids have been developed to enhance medicinal properties and target specificity.
Purpose:
- To explore the potential therapeutic applications of retinoids in autoimmune diseases.
- To investigate the efficacy of specific synthetic retinoids, like tamibarotene (Am80), in preclinical models of autoimmune conditions.
Summary:
- Tamibarotene (Am80) is a synthetic retinoid selectively targeting RARalpha and RARbeta, sparing RARgamma and RXRs.
- Tamibarotene demonstrates efficacy in treating psoriasis and relapsed APL patients.
- Experimental studies show tamibarotene's activity in animal models of rheumatoid arthritis and experimental autoimmune encephalomyelitis.
Impact:
- Retinoids, particularly tamibarotene, represent a promising class of therapeutics for autoimmune diseases.
- Targeting Th1-dominant autoimmune conditions with retinoids may offer novel treatment strategies.
- Further research into retinoid mechanisms could lead to new therapies for debilitating autoimmune disorders.